By: IPP Bureau
Last updated : May 01, 2026 5:29 pm
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Laurus Labs reported robust financial performance for FY26: revenue rose 23% year-on-year to Rs 6,813 crore and EBITDA increasing 64% to Rs 1,826 crore, supported by strong momentum in its CDMO and affordable medicines businesses.
The company posted EBITDA margins of 26.8% for the year, improving by 6.7 percentage points over FY25, while net profit surged 148% to Rs 889 crore. Gross margins improved to 60.4% from 55.4% a year earlier, aided by a favourable product mix and higher contribution from CDMO operations.
For the fourth quarter of FY26, Laurus Labs reported revenues of Rs 1,812 crore, a 5% year-on-year increase, while EBITDA grew 10% to Rs 523 crore. Quarterly EBITDA margins stood at 28.9%.
Satyanarayana Chava, Founder and Chief Executive Officer, said the company significantly accelerated its performance in FY26 through commercial supplies for NCE programs, new product launches, and continued leadership in the anti-retroviral segment.
V. V. Ravi Kumar, Executive Director and Chief Financial Officer, said the company’s performance reflected strong demand across integrated CDMO offerings and affordable medicines businesses. He noted that operational leverage and product mix improvements helped strengthen profitability during the year.
The CDMO business delivered FY26 revenues of Rs 2,080 crore, up 36% year-on-year, driven by commercial NCE API supplies, late-stage pipeline projects and sustained demand across complex chemistry platforms. Small molecule CDMO revenues rose 38% to Rs 1,896 crore, while the Bio division posted 15% annual growth to Rs 184 crore